TriRx Pharmaceutical Services, LLC, an international CDMO, hosted a ribbon-cutting ceremony, Tuesday, August 10, with city leaders, representatives from The University of Kansas, Kansas State University, and key customers, to commemorate the acquisition of the Shawnee facility previously owned by Elanco Animal Health.
 
TriRx also finalized the site’s long-term supply agreement with Elanco Animal Health, a global innovative provider of products and services to prevent and treat disease in farm animals and pets.
 
Timothy C. Tyson, Chairman and CEO of TriRx, said, “We are proud that so many Kansas state leaders, stewards of the city of Shawnee, state universities, and key customers and partners joined the TriRx team to commemorate this exciting milestone.”
 
On August 1, 2021, TriRx finalized and closed on an agreement with Elanco Animal Health to acquire the ownership and operations of its manufacturing site in Shawnee, KS. The Shawnee facility, employing approximately 300 personnel, offers contract manufacturing capabilities to human and animal health pharmaceutical clients.
 
The long-term supply agreement will assure a reliable supply of Elanco’s products and provide a solid foundation for the site’s operations. Increasing the utilization and efficiency of the facility, TriRx will contract manufacture products for a growing portfolio of customers, including human health clients.
 
“Investment in the Shawnee facility and the highly skilled people critical to its operation are key components of our strategic plan,” Tyson added. “We see much opportunity ahead as TriRx continues to strengthen its position as a leading contract development and manufacturing organization active in both the human and animal health markets.”
 
Manufacturing capabilities at the Shawnee site include parenterals, topicals, non-sterile liquids, solid oral dose, and soft chews. The facility also features a pilot plant, quality control laboratories, veterinary technical services, and a large warehousing and distribution facility.